Stocks Screener

Specify Company / Ticker to Get the Summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Dividend History HRMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Dividend Analytics HRMY

Max Ratio

5Y Dividend Growth

Consecutive Years

5Y Average Payout Ratio

Forward Annual Dividend Yield
Consecutive Years
Forward Annual Dividend – USD
Consistent Years
Dividend CAGR 3Y
Continuous Dividends
Dividend CAGR 5Y
Payout Ratio TTM
Dividend CAGR 10Y
Ex Dividend Date

Harmony Biosciences Holdings

HRMY
Current price
35.20 USD -1.25 USD (-3.43%)
Last closed 36.43 USD
ISIN US4131971040
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 2 091 967 232 USD
Yield for 12 month +5.23 %
1Y
3Y
5Y
10Y
15Y
HRMY
21.11.2021 - 28.11.2021

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 1 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome (FXS), rare genetic disorder that causes inherited intellectual disability and autism spectrum disorder; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; and EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies (DEE). The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Address: 630 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

51.56 USD

P/E Ratio

13.90

Dividend Yield

Financials HRMY

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Key Figures HRMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021

Current Year

+714 734 000 USD

Last Year

+582 022 000 USD

Current Quarter

+184 733 000 USD

Last Quarter

+201 267 000 USD

Current Year

+557 919 000 USD

Last Year

+460 786 000 USD

Current Quarter

+152 739 000 USD

Last Quarter

+146 858 000 USD
EBITDA 218 994 000 USD
Operating Margin TTM 30.45 %
Price to Earnings 13.90
Return On Assets TTM 12.81 %
PEG Ratio
Return On Equity TTM 24.71 %
Wall Street Target Price 51.56 USD
Revenue TTM 744 851 968 USD
Book Value 12.55 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 19.50 %
Dividend Yield
Gross Profit TTM 583 526 976 USD
Earnings per share 2.62 USD
Diluted Eps TTM 2.62 USD
Most Recent Quarter I 2025
Quarterly Earnings Growth YOY 16.40 %
Profit Margin 20.50 %

Stock Valuation HRMY

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 13.90
Forward PE 9.83
Enterprise Value Revenue 2.36
Price Sales TTM 2.81
Enterprise Value EBITDA 7.40
Price Book MRQ 2.90

Technical Indicators HRMY

For 52 Weeks

26.47 USD 41.61 USD
50 Day MA 33.51 USD
Shares Short Prior Month 3 706 527
200 Day MA 34.19 USD
Short Ratio 5.76
Shares Short 4 415 410
Short Percent 14.16 %